Halozyme Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$23.5M
Doctors Paid
698
Transactions
7,723
2024 Total
$103,295
Payment Breakdown by Category
Research$22.9M (97.4%)
Consulting$401,811 (1.7%)
Travel$89,018 (0.4%)
Food & Beverage$42,230 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22.9M | 5,791 | 97.4% |
| Consulting Fee | $401,811 | 80 | 1.7% |
| Travel and Lodging | $89,018 | 215 | 0.4% |
| Food and Beverage | $42,230 | 1,612 | 0.2% |
| Grant | $40,000 | 4 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,970 | 9 | 0.1% |
| Honoraria | $13,500 | 6 | 0.1% |
| Education | $76.86 | 6 | 0.0% |
Payments by Type
Research
$22.9M
5,791 transactions
General
$617,605
1,932 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | $4.3M | 3 | 793 |
| A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors | $3.8M | 0 | 538 |
| A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | $3.7M | 0 | 2,917 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects Wit | $2.7M | 3 | 444 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant | $2.5M | 3 | 533 |
| A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel and Gemcitabine Compared to nab-Paclitaxel in Subjects with Stage IV Previously Untreated Pancreatic Cancer | $2.1M | 0 | 405 |
| HVAI PHASE 1 TRIAL | $1.0M | 0 | 12 |
| Effects of targeted HA depletion on the immune response and pathogenesis of PDA | $485,797 | 0 | 2 |
| Hyaluronan as a Predictive and Prognostic Marker for Pancreatic Ductal Adenocarcinoma and Lung Cancer Study | $309,271 | 0 | 5 |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | $268,531 | 0 | 82 |
| A Phase 1b/2, Randomized, Multicenter, Multinational Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Docetaxel (PDoc) Compared With Docetaxel (Doc) alone in Subjects with Recurrent Previously Treated Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | $150,829 | 0 | 42 |
| Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | $106,375 | 0 | 1 |
| Assessment of muscle pain after PEGPH20 injection in preclinical models | $96,752 | 0 | 1 |
| Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab | $28,776 | 0 | 2 |
| Evaluation of the Pharmacological Activity of PEGPH20 in an Orthotopic Model of Pancreatic Ductal Adenocarcinoma (PDAC) | $11,000 | 0 | 1 |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine | $10,750 | 0 | 5 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Darren Brennan, M.d, M.D | Diagnostic Radiology | Marlborough, MA | $60,475 | $0 |
| Keith Mccrae, Md, MD | Hematology & Oncology | Cleveland, OH | $47,199 | $0 |
| Dr. Mahesh Krishnan, Md Mph Fasn, MD MPH FASN | Nephrology | Mc Lean, VA | $42,125 | $0 |
| Dr. Joseph Hoffman, M.d, M.D | Pulmonary Disease | Park Ridge, NJ | $18,155 | $0 |
| Dr. Kenneth Yu, M.d., M.sc, M.D., M.SC | Internal Medicine | New York, NY | $16,916 | $0 |
| Patricia Lorusso, Do, DO | Internal Medicine | Detroit, MI | $16,208 | $0 |
| Andrea Bullock, M.d, M.D | Internal Medicine | Boston, MA | $15,462 | $0 |
| Sunil Hingorani, Md, Phd, MD, PHD | Medical Oncology | Seattle, WA | $10,980 | $0 |
| Dr. Vaibhav Sahai, M.d, M.D | Hematology & Oncology | Ann Arbor, MI | $9,787 | $0 |
| Dr. Andrew Hendifar, Md, Mph, MD, MPH | Internal Medicine | West Hollywood, CA | $8,386 | $0 |
| Dr. Philip Philip, Md Phd Frcp, MD PHD FRCP | Internal Medicine | Detroit, MI | $8,131 | $0 |
| Dr. Rachna Shroff, Md, MD | Hematology & Oncology | Tucson, AZ | $7,507 | $0 |
| Tara Seery | Hematology & Oncology | Irvine, CA | $7,469 | $0 |
| Dr. Carl Peck, M.d, M.D | Clinical Pharmacology | San Luis Obispo, CA | $5,735 | $0 |
| Mr. Mitesh Borad, Md, MD | Medical Oncology | Scottsdale, AZ | $5,361 | $0 |
| Dr. Alan Venook, Md, MD | Internal Medicine | San Francisco, CA | $4,618 | $0 |
| Joel Hecht, Md, MD | Gastroenterology | Los Angeles, CA | $4,421 | $0 |
| Howard Hochster, M.d, M.D | Hematology | New Haven, CT | $4,290 | $0 |
| Dr. Paul Ritch, Md, MD | Medical Oncology | Milwaukee, WI | $4,029 | $0 |
| Andrew Lowy, Md, MD | Surgical Oncology | San Diego, CA | $4,000 | $0 |
| Roy Herbst, M.d., Phd, M.D., PHD | Medical Oncology | Houston, TX | $4,000 | $0 |
| Anil Rustgi, Md, MD | Internal Medicine | New York, NY | $3,936 | $0 |
| Jonathan Kurie, M.d, M.D | Medical Oncology | Houston, TX | $3,434 | $0 |
| Dr. Alok Khorana, M.d, M.D | Hematology & Oncology | Rochester, NY | $3,370 | $0 |
| Ghassan Abou-Alfa, Md, MD | Medical Oncology | New York, NY | $3,305 | $0 |
Ad
Top Products
- Hylenex $27,358
- HYLENEX RECOMBINANT $10,320
Associated Products (2)
- Hylenex $27,358
- HYLENEX RECOMBINANT $15,024
Payment Categories
- Food & Beverage $42,230
- Consulting $401,811
- Travel & Lodging $89,018
- Research $22.9M
About Halozyme Inc
Halozyme Inc has made $23.5M in payments to 698 healthcare providers, recorded across 7,723 transactions in the CMS Open Payments database. In 2024, the company paid $103,295. The top product by payment volume is Hylenex ($27,358).
Payments were distributed across 64 medical specialties. The top specialty by payment amount is Hematology & Oncology ($97,195 to 26 doctors).
Payment categories include: Food & Beverage ($42,230), Consulting ($401,811), Research ($22.9M), Travel & Lodging ($89,018).
Halozyme Inc is associated with 2 products in the CMS Open Payments database.